Nordisk
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
GLP-1, addiction treatment, semaglutide, clinical trials, Novo Nordisk
Novo Nordisk Slashes Wegovy Price for Cash-Paying Patients
Wegovy, price cut, Novo Nordisk, NovoCare Pharmacy, obesity treatment, semaglutide, direct-to-patient, cash-paying patients
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026
Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval
Novo Nordisk Projects Slower Growth for 2025 Despite Wegovy’s Strong Q4 Performance
Novo Nordisk, Wegovy, obesity drugs, sales growth, 2025 outlook, pharmaceutical industry
Omega Therapeutics Faces Bankruptcy and Layoffs Despite Recent Novo Nordisk Obesity Deal
Omega Therapeutics, bankruptcy, layoffs, Novo Nordisk, obesity deal, Flagship Pioneering, epigenomics, financial struggles
Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%
Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry
High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial
Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial
Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial
Novo Nordisk, Wegovy, semaglutide, obesity treatment, weight loss, Phase IIIb trial, STEP UP trial
Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies
Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry